Janssen

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

November 7, 2023

•

Fineline Cube

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B virus (HBV)-targeted siRNA antiviral JNJ-3989 from Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen. The agreement includes Arrowhead Pharmaceuticals, the original discoverer of the investigational drug, which was initially licensed to Janssen in 2018. GSK’s…
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

September 7, 2023

•

Fineline Cube

Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on a late-stage study for its bispecific antibody (BsAb) Rybrevant (amivantamab). The study investigated the combination of Rybrevant with tyrosine kinase inhibitor (TKI) lazertinib and chemotherapy in treating advanced or metastatic non-small cell lung cancer (NSCLC)…

Fineline Info & Tech